Hamid Bakherad

500 total citations
26 papers, 396 citations indexed

About

Hamid Bakherad is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Hamid Bakherad has authored 26 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Immunology. Recurrent topics in Hamid Bakherad's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Immunotherapy and Immune Responses (6 papers) and Glycosylation and Glycoproteins Research (5 papers). Hamid Bakherad is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Immunotherapy and Immune Responses (6 papers) and Glycosylation and Glycoproteins Research (5 papers). Hamid Bakherad collaborates with scholars based in Iran, Canada and South Africa. Hamid Bakherad's co-authors include Hamed Zare, Seyed Latif Mousavi Gargari, Walead Ebrahimizadeh, Masoumeh Rajabibazl, Iraj Rasooli, Mohammad Heiat, Hossein Aghamollaei, Javad Nazarian, Roghayyeh Baghban and Mohammadali Mohammadi and has published in prestigious journals such as Analytical Biochemistry, Scientific Reports and Applied Microbiology and Biotechnology.

In The Last Decade

Hamid Bakherad

25 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hamid Bakherad Iran 13 233 205 97 55 54 26 396
Dae Young Kim South Korea 12 219 0.9× 125 0.6× 57 0.6× 19 0.3× 44 0.8× 23 358
Lucía F. Zacchi Australia 12 306 1.3× 31 0.2× 63 0.6× 16 0.3× 119 2.2× 26 509
Ron Alcalay Israel 13 149 0.6× 67 0.3× 217 2.2× 19 0.3× 63 1.2× 34 377
Katherine F. Warfel United States 8 247 1.1× 72 0.4× 28 0.3× 57 1.0× 22 0.4× 12 301
Brian J. Fennell Ireland 11 256 1.1× 207 1.0× 109 1.1× 10 0.2× 26 0.5× 15 450
Sudharsan Sridharan United Kingdom 12 322 1.4× 116 0.6× 34 0.4× 15 0.3× 166 3.1× 12 495
Laurence J. Altobell United States 9 238 1.0× 104 0.5× 46 0.5× 18 0.3× 15 0.3× 9 353
Vasanthi Ramachandiran United States 9 220 0.9× 38 0.2× 79 0.8× 33 0.6× 15 0.3× 11 306
Keith A. Charlton United Kingdom 11 213 0.9× 160 0.8× 41 0.4× 50 0.9× 8 0.1× 17 342
James W. Stave United States 11 298 1.3× 72 0.4× 44 0.5× 16 0.3× 10 0.2× 12 406

Countries citing papers authored by Hamid Bakherad

Since Specialization
Citations

This map shows the geographic impact of Hamid Bakherad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hamid Bakherad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hamid Bakherad more than expected).

Fields of papers citing papers by Hamid Bakherad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hamid Bakherad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hamid Bakherad. The network helps show where Hamid Bakherad may publish in the future.

Co-authorship network of co-authors of Hamid Bakherad

This figure shows the co-authorship network connecting the top 25 collaborators of Hamid Bakherad. A scholar is included among the top collaborators of Hamid Bakherad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hamid Bakherad. Hamid Bakherad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bakherad, Mohammad, et al.. (2025). Synthesis, QSAR modeling, and molecular docking studies of 1,2,3-triazole-pyrazole hybrids as significant anti-cancer and anti-microbial agents. Journal of Molecular Structure. 1335. 141851–141851. 1 indexed citations
2.
Bakherad, Mohammad, et al.. (2024). Synthesis, and molecular docking studies of novel 1,2,3-triazoles-linked pyrazole carboxamides as significant anti-microbial and anti-cancer agents. Results in Chemistry. 11. 101842–101842. 3 indexed citations
3.
Gargari, Seyed Latif Mousavi, et al.. (2024). In silico designing and optimization of anti‐epidermal growth factor receptor scaffolds by complementary‐determining regions‐grafting technique. Quantitative Biology. 12(3). 301–312. 1 indexed citations
4.
5.
Zare, Hamed, et al.. (2023). Introduction of a new recombinant vaccine based on GRP78 for breast cancer immunotherapy and evaluation in a mouse model. Bioimpacts. 14(2). 27829–27829. 5 indexed citations
6.
Zare, Hamed, et al.. (2023). Covid-19 Prevention and Treatment by Targeting Fc-fusionProteins: An Experience to Fight Emerging Diseases. Current Molecular Medicine. 24(4). 428–434. 1 indexed citations
7.
Meimandipour, Amir, Jamal Fayazi, Ali Asghar Karkhane, et al.. (2023). Biochemical and molecular characterization of novel keratinolytic protease from Bacillus licheniformis (KRLr1). Frontiers in Microbiology. 14. 1132760–1132760. 18 indexed citations
8.
Gargari, Seyed Latif Mousavi, et al.. (2023). Anti-EGFR bioengineered bacterial outer membrane vesicles as targeted immunotherapy candidate in triple-negative breast tumor murine model. Scientific Reports. 13(1). 16403–16403. 12 indexed citations
9.
10.
Bakherad, Hamid, et al.. (2022). Nanobodies; new molecular instruments with special specifications for targeting, diagnosis and treatment of triple-negative breast cancer. Cancer Cell International. 22(1). 245–245. 12 indexed citations
11.
Aria, Hamid, et al.. (2022). Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review. Analytical Biochemistry. 640. 114546–114546. 23 indexed citations
12.
Bakherad, Hamid, Saghi Sepehri, Mohammad Ali Faramarzi, et al.. (2022). In silico and in vitro studies of thiosemicarbazone-indole hybrid compounds as potent α-glycosidase inhibitors. Computational Biology and Chemistry. 97. 107642–107642. 16 indexed citations
13.
Shakour, Neda, et al.. (2022). Design, synthesis, and in silico studies of tetrahydropyrimidine analogs as urease enzyme inhibitors. Archiv der Pharmazie. 355(10). e2200158–e2200158. 12 indexed citations
14.
Bakherad, Hamid, et al.. (2021). Nanobodies: a tool to open new horizons in diagnosis and treatment of prostate cancer. Cancer Cell International. 21(1). 580–580. 23 indexed citations
15.
Bakherad, Hamid, Zargham Sepehrizadeh, Neda Setayesh, et al.. (2020). Expression of recombinant G-CSF receptor domains and their inhibitory role on G-CSF function. Research in Pharmaceutical Sciences. 15(4). 381–381. 1 indexed citations
16.
Zare, Hamed, et al.. (2020). Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review. Molecular and Cellular Probes. 55. 101692–101692. 25 indexed citations
17.
Aghamollaei, Hossein, et al.. (2020). Evaluation of a Cationic Antimicrobial Peptide as the New Antibiotic Candidate to Treat Staphylococcus aureus Keratitis. International Journal of Peptide Research and Therapeutics. 27(1). 755–762. 2 indexed citations
18.
Bakherad, Hamid, Seyed Latif Mousavi Gargari, Zargham Sepehrizadeh, et al.. (2017). Identification and in vitro characterization of novel nanobodies against human granulocyte colony-stimulating factor receptor to provide inhibition of G-CSF function. Biomedicine & Pharmacotherapy. 93. 245–254. 15 indexed citations
19.
Gargari, Seyed Latif Mousavi, Iraj Rasooli, Mohammadali Mohammadi, et al.. (2013). A novel nanobody against urease activity of Helicobacter pylori. International Journal of Infectious Diseases. 17(9). e723–e728. 44 indexed citations
20.
Bakherad, Hamid, Seyed Latif Mousavi Gargari, Iraj Rasooli, et al.. (2013). In Vivo Neutralization of Botulinum Neurotoxins Serotype E with Heavy-chain Camelid Antibodies (VHH). Molecular Biotechnology. 55(2). 159–167. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dae Young Kim Breakdown of academic impact, for papers by Lucía F. Zacchi Breakdown of academic impact, for papers by Ron Alcalay Breakdown of academic impact, for papers by Katherine F. Warfel Breakdown of academic impact, for papers by Brian J. Fennell Breakdown of academic impact, for papers by Sudharsan Sridharan Breakdown of academic impact, for papers by Laurence J. Altobell Breakdown of academic impact, for papers by Vasanthi Ramachandiran Breakdown of academic impact, for papers by Keith A. Charlton Breakdown of academic impact, for papers by James W. Stave
Rankless by CCL
2026